Omada Health launches internal tool and new platform capabilities

Omada Health, a virtual care provider, launched its internal initiative that uses cross-functional data to drive its healthcare program, Omada Insights Lab. In addition, the AI company launched its Physician-Guided Care program for diabetes and hypertension, as well as enhanced musculoskeletal personalized physical therapy treatment.

The lab leverages data across five teams: data science, behavior science, clinical design, product design, and care delivery to optimize its programs across a host of health conditions. Omada is funded by some heavy hitters in the healthcare space, including insurance giant Cigna

The virtual provider recently conducted an analysis of its diabetes care program, revealing care team feedback as a top driver of weight loss. Member care team rapport also correlated strongly with health outcomes, and members who interacted with their care team were 24% more likely to achieve their health goals. Members who messaged their care teams were twice as likely to achieve positive health outcomes. The insights enabled Omada to decrease automated nudges and strengthen the member-team relationship.

“The wellness industry has historically focused on incentivizing and nudging members to boost short-term engagement at the cost of long-term outcomes,” Jennifer La Guardia, PhD, director of clinical product and behavior science at Omada Health, said in a statement.

The Omada Insights Lab leveraged more than a billion data points from its 450,000 members’ interactions over the last decade to determine such insights.

Omada also recently launched its Physician-Guided Care program for diabetes and hypertension, creating the first virtual cardiometabolic clinic. 

“Members will now have access to behavior change support, diabetes/hypertension management and education, devices and monitoring, and medical management of diabetes, hypertension, and dyslipidemia all in one place,” the announcement reads.

In addition, its new physical therapy capabilities include personalized treatment for members with new computer vision technology that allows data to inform treatment decisions. 

“The computer vision technology that we have developed has the potential to reinvent the way we think about musculoskeletal care,” said Todd Norwood, PT, DPT, director of clinical services at Omada Health. “By leveraging the data collected with digital tools in tandem with programs that are based in the science of behavior change, we can help people improve their health both short and long term.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.